Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Biomédica (Bogotá) ; 36(4): 498-503, dic. 2016. tab, graf
Article in Spanish | LILACS | ID: biblio-950914

ABSTRACT

RESUMEN La enfermedad renal asociada a cadenas ligeras es frecuente en el contexto de las gammapatías monoclonales, afecta los glomérulos o los túbulos renales, y su causa más común es el mieloma múltiple. Puede desarrollarse después de un trasplante renal por recurrencia de un mieloma múltiple ya existente, o puede ser de diagnóstico nuevo y presentarse con deterioro de la función renal y proteinuria. Siempre se requiere una biopsia renal para confirmar el diagnóstico.


ABSTRACT Light chain-associated kidney compromise is frequent in patients with monoclonal gammopathies; it affects the glomeruli or the tubules, and its most common cause is multiple myeloma. It may develop after a kidney transplant due to recurrence of a preexisting multiple myeloma or it can be a de novo disease manifesting as graft dysfunction and proteinuria. A kidney biopsy is always necessary to confirm the diagnosis.


Subject(s)
Aged , Humans , Male , Middle Aged , Kidney Transplantation/adverse effects , Primary Graft Dysfunction/etiology , Multiple Myeloma/etiology , Proteinuria/etiology , Biopsy , Myeloma Proteins/analysis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation , Immunoglobulin Light Chains/analysis , Fatal Outcome , Combined Modality Therapy , Immunosuppressive Agents/adverse effects , Kidney Failure, Chronic/surgery , Multiple Myeloma/diagnosis , Multiple Myeloma/therapy
2.
Rev. cuba. hematol. inmunol. hemoter ; 29(2): 183-188, abr.-jun. 2013.
Article in Spanish | LILACS | ID: lil-672147

ABSTRACT

Introducción: el mieloma múltiple (MM) es una enfermedad caracterizada por una proliferación monoclonal de inmunoglobulinas que representa aproximadamente el 15 por ciento de las hemopatías malignas. Métodos: se realizó un estudio de la distribución de las clases, sub clases y tipos de cadenas ligeras de inmunoglobulinas en 285 enfermos con el diagnóstico de MM. Se emplearon tres métodos: electroforesis de proteínas en suero para la detección de la inmunoglobulina monoclonal o paraproteína, electroforesis de inmunofijación y doble inmunodifusión para identificar las clases, sub clases y tipo de cadenas ligeras. Resultados: se encontraron 206 enfermos (72.28 por ciento) con MM IgG; 73 (25.62 por ciento) con MM IgA y 6 (2.1 por ciento) con MM IgM. La distribución de sub clases de IgG fue: 130 casos (63.11 por ciento) IgG1, 43 (20.87 por ciento) IgG2, 21 (10.19 porciento) IgG3 y 12 (5.83 por ciento) IgG4; y la de sub clases de IgA fue de 59 enfermos (80.82 por ciento) IgA1 y 14 (19.18 por ciento) IgA2. Del total de enfermos 187 (65.61 por ciento) mostraron cadenas ligeras tipo kappa y 98 (34.38 por ciento) tipo lambda. Conclusiones: los datos obtenidos en nuestro estudio permitieron identificar la frecuencia de distribución de las clases, subclases y cadenas ligeras en una muestra de enfermos con MM


Introduction: multiple mieloma (MM) is a disease characterized by a monoclonal proliferation of immunoglobulins representing approximately 15 percent of malignant hemopathies. Methods: the distribution of classes, subclasses and light chains of monoclonal immunoglobulins was studied in 285 patients with MM. Three methods were used: serum protein electrophoresis for the detection of monoclonal immunoglobulins or paraproteins, immunofixation electrophoresis and double immunodiffusion to identify classes, subclasses and light chain types. Results: 206 patients (72.28 percent) with IgG MM, 73 (25,62 percent) with IgA MM, and 6 (2,1 percent) with IgM MM were found. The distribution of IgG subclasses was: 130 cases (63,11 percent) IgG1; 43 (20,87 percent) IgG2; 21 (10,19 percent) IgG3: and 12 (5,83 percent) IgG4. Distribution of IgA subclasses was: 59 patients (80,82 percent) IgA1 and 14 (19,18 percent) IgA2; 187 patients (65,62 percent) showed kappa light chains and 98 (34,38 percent) were lambda. Conclusions: the data obtained in our study allowed us to identify the frequency of distribution of classes, subclasses and light chains in a sample of patients with MM


Subject(s)
Hemoglobin A/analysis , Multiple Myeloma/complications , Paraproteins/analysis , Myeloma Proteins/analysis , Immunoglobulin kappa-Chains/analysis , Blood Protein Electrophoresis/methods , Electrophoresis/methods , Immunoglobulin Light Chains
4.
Indian J Pathol Microbiol ; 2004 Oct; 47(4): 506-8
Article in English | IMSEAR | ID: sea-75735

ABSTRACT

In setting up a diagnostic myeloma laboratory the popular, highly automated and otherwise excellent choices of equipment and laboratory practices, so exorbitantly raise costs that the sustainability, even in large government hospitals in third world countries may become difficult. Based on our experience in a regional cancer center in India, we offer here, guidelines for carrying out high resolution electrophoresis, densitometry, immunofixation and urine concentration. We show that by simply employing well established techniques and doing them properly, one can get results of excellent quality at minimum cost and minimum dependence on costly imports.


Subject(s)
Blood Protein Electrophoresis/economics , Costs and Cost Analysis , Densitometry/economics , Humans , Immunoassay/economics , India , Laboratories, Hospital/economics , Clinical Laboratory Techniques/economics , Multiple Myeloma/diagnosis , Myeloma Proteins/analysis , Urinalysis/economics
5.
Acta méd. colomb ; 14(5): 333-5, sept.-oct. 1989. tab
Article in Spanish | LILACS | ID: lil-292782

ABSTRACT

Se describe una paciente con mieloma múltiple tipo IgA con un inhibidor de la coagulación de tipo heparinoide, no inmune ni relacionada con la paraproteina. Fue identificado por pruebas de neutralización con sulfato de protamina, con una concentración plasmatica menor de 0.3 U/mL. Se discute la naturaleza de este tipo de inhibidores y su relación con las neoplasias


Subject(s)
Humans , Female , Middle Aged , Blood Coagulation/immunology , Heparinoids/immunology , Multiple Myeloma/immunology , Myeloma Proteins/analysis
6.
7.
SELECTION OF CITATIONS
SEARCH DETAIL